
The global pharma industry drug pipeline is bursting with more than 3,800 injectable drugs of which more than 70% are biologics in clinical phases

Fabian, having joint SCHOTT AG in 2012, is Vice President Global Strategy & Innovation for the SCHOTT Business Unit Pharmaceutical Systems Within the management team he is responsible for strategy, product management, product development, IP management and market intelligence covering ampoules, cartridges, pre-filled syringes and vials for injectable use. Prior to this, he was heading the corporate strategy department of SCHOTT AG being responsible for corporate development, strategic planning and portfolio management of the whole group.Fabian studied business administration at the University of Cologne/Germany and the Corvinus University of Budapest/Hungary and holds an MBA from the University of Cologne. He is a Chartered Financial Analyst (CFA) charterholder from the CFA Institute, Charlottesville/USA.

The global pharma industry drug pipeline is bursting with more than 3,800 injectable drugs of which more than 70% are biologics in clinical phases

Published: June 30th 2020 | Updated: